
The study compared SGLT2is to dipeptidyl peptidase‐4 inhibitors (DPP4is), found significantly lower risks of amputation with SGLT2is in certain patient subgroups, including those with baseline cardiovascular disease and diuretic use. The findings suggest that initiating SGLT2is did not increase amputation risk and can be considered safe for selected high‐risk patients with type 2 diabetes. The results offer reassurance to clinicians regarding SGLT2is safety in vulnerable populations.
Like
Save
Share